EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece

Epameinondas Koumpis, Eva Minga, Persefoni Talimtzi, Maria Angelopoulou, Sofia Chatzileontiadou, Maria Dimou, Sotiria Besikli-Dimou, Maria Efstathopoulou, Dimitris Gogos, Evdoxia Hatjiharissi, Eleftheria Hatzimichael, Michail Iskas und 16 weitere

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-07161-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Epameinondas Koumpis und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Faculty of Medicine, University of Ioannina, Greece, Ioannina, Greece. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre for Research & Technology Hellas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aims to characterize treatment patterns for chronic lymphocytic leukemia (CLL) in real-world clinical practice across Greece focusing on both treatment-naïve and relapsed or refractory (R/R) disease. We evaluated therapeutic patterns and outcomes [including overall survival (OS), time to next treatment or death (TTNT-D) and overall response rate (ORR)] and documented the incidence of other malignancies of patients who initiated first-line treatment between 2010 and 2024.

Methods

This is a panhellenic multicenter retrospective study of patients diagnosed with CLL between 2010 and 2020 from 8 centers in Greece.

Results

Overall, 1318 patients were included in the study. Fludarabine, cyclophosphamide and rituximab (FCR) was the most common first-line regimen (21.6%), followed by chlorambucil plus rituximab (16.3%) and ibrutinib-based therapies (14%). In the R/R setting, ibrutinib and venetoclax-based treatments, became the predominant therapeutic choices after 2014, replacing chemoimmunotherapy. Shifts in treatment patterns before and after 2016 reflected the incorporation of targeted agents into routine clinical practice, with a marked decline in FCR use and increased adoption of targeted therapies. Median OS was 162 months from diagnosis and 105.2 months (95% CI: 90.3–116.3) from first treatment. In patients receiving ibrutinib as first-line therapy, mOS was not reached, and median TTNT-D was 67.3 months. Overall, 18 (1.4%) cases developed a second hematological malignancy and 59 (4.5%) were diagnosed with a solid tumor. The most common hematological malignancy was myelodysplastic neoplasms and the most common solid tumors included lung, skin, breast, colon and prostate cancers.

Conclusion

The findings suggest a gradual shift in CLL treatment patterns in Greece, with targeted agents increasingly replacing traditional chemoimmunotherapy in recent years and showing favorable survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesGreeceMaleFemaleRituximabAged, 80 and overAgedTreatment OutcomeCyclophosphamideMiddle AgedChlorambucilPiperidinesVidarabineAdenineBridged Bicyclo Compounds, HeterocyclicSulfonamidesSurvival Rate

Stichwörter der Autor:innen

CLLGreeceTargeted agentsTreatment patterns

Substanzen

RituximabCyclophosphamideChlorambucilPiperidinesVidarabineAdenineBridged Bicyclo Compounds, HeterocyclicSulfonamidesibrutinibfludarabine

Autor:innen und Institutionen

  • Department of Haematology, Faculty of Medicine, University of Ioannina, Greece, Ioannina, Greece.
  • Institute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece.
  • Haematology, University of Athens, Laikon General Hospital, Athens, Greece.
  • 1st Dept of Internal Medicine, Hematology Unit, AUTH, AHEPA Hospital, Thessaloniki, Greece.
  • Hematology Department and HCT Unit G. Papanicolaou Hospital Thessaloniki, Thessaloniki, Greece.
  • Department of Haematology, Athens Medical Center, Athens, Greece.

Förderung

  • Centre for Research & Technology Hellas

Zitieren

APA

Koumpis, E., Minga, E., Talimtzi, P., Angelopoulou, M., Chatzileontiadou, S., Dimou, M., Besikli-Dimou, S., Efstathopoulou, M., Gogos, D., Hatjiharissi, E., Hatzimichael, E., Iskas, M., Konstantinou, E., Kotsianidis, I., Machairas, A., Mpalaoura, E., Mpanti, A., Panagiotidis, P., Pangalis, G., …, & Chatzikonstantinou, T. (2026). Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece. Annals of Hematology. https://doi.org/10.1007/s00277-026-07161-3

Vancouver

Koumpis E, Minga E, Talimtzi P, Angelopoulou M, Chatzileontiadou S, Dimou M, et al. Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece. Annals of Hematology. 2026. doi:10.1007/s00277-026-07161-3

BibTeX
@article{Koumpis2026,
  author = {Koumpis, Epameinondas and Minga, Eva and Talimtzi, Persefoni and Angelopoulou, Maria and Chatzileontiadou, Sofia and Dimou, Maria and Besikli-Dimou, Sotiria and Efstathopoulou, Maria and Gogos, Dimitris and Hatjiharissi, Evdoxia and Hatzimichael, Eleftheria and Iskas, Michail and Konstantinou, Eliana and Kotsianidis, Ioannis and Machairas, Alexandros and Mpalaoura, Eugenia and Mpanti, Anastasia and Panagiotidis, Panagiotis and Pangalis, Gerasimos and Papadopoulos, Ioannis and Papaioannou, Maria and Siakantaris, Marina and Stavroyianni, Niki and Vassilakopoulos, Theodoros and Vrachiolias, George and Stamatopoulos, Kostas and Chatzidimitriou, Anastasia and Chatzikonstantinou, Thomas},
  title = {Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07161-3}
}
Kostenlos starten →